CYFRA 21-1 serum analysis in patients with esophageal cancer.
CYFRA 21-1 serum analysis in patients with esophageal cancer.
复制标题
DOI：
--
复制
发表时间：
2000-11
期刊：
影响因子：
--
通讯作者：
Jens Brockmann;H. Nottberg;B. Glodny;A. Heinecke;N. Senninger
中科院分区：
文献类型：
--
作者：
Jens Brockmann;H. Nottberg;B. Glodny;A. Heinecke;N. Senninger
进行该研究以确定CYFRA 21-1在患有食管癌的患者中的潜在用途。将50例经组织学证实的食管恶性病变患者与50例健康人、50例良性食管疾病患者和50例良性肺病患者的血清CYFRA 21-1浓度进行比较。对血清癌胚抗原、CA 72-4和鳞状细胞癌抗原血清浓度进行了额外分析。对食管癌患者每3个月进行一次肿瘤标志物检查，随访1年。进行分析以检测统计学显着差异，以估计临界值并评估肿瘤实体、肿瘤分期、生存期和无肿瘤生存期。截止值为1.40 ng/ml的CYFRA 21-1显示对食管癌的总体敏感性为36%（鳞状细胞癌为45.5%，腺癌为17.6%），特异性为97.3%。CYFRA 21-1浓度显示出取决于局部肿瘤负荷的更高血清水平的趋势。未观察到CYFRA 21-1与各种N期或M期疾病的相关性。术后生存率和无瘤生存率的发展与术前CYFRA 21-1浓度显著相关。临床肿瘤复发之前CY-FRA 21-1升高3.4个月。对于预后和随访，该标志物是合理的，在一个更大的系列患有食管癌的患者进行额外的分析。
This study was conducted to determine a potential use of CYFRA 21-1 in patients suffering from carcinoma of the esophagus. CYFRA 21-1 serum concentrations of 50 patients with histologically proven malignant lesion of the esophagus were compared with 50 healthy persons, 50 patients with benign esophageal disease, and 50 patients with benign lung disease. Additional analysis of serum carcinoembryonic antigen, CA 72-4, and squamous cell carcinoma-antigen serum concentrations were performed. The patients with esophageal carcinoma underwent follow-up tumor marker examinations every three months for 1 year. Analysis to detect statistically significant differences was conducted to estimate a cutoff and to evaluate tumor entity, tumor stage, survival, and tumor-free survival. CYFRA 21-1 at a cutoff of 1.40 ng/ml showed an overall sensitivity to esophageal carcinoma of 36% (45.5% to squamous cell carcinoma, 17.6% to adenocarcinoma) at a specificity of 97.3%. CYFRA 21-1 concentrations showed a tendency to higher serum levels depending on local tumor burden. A correlation of CYFRA 21-1 with various N- or M-stage disease was not observed. Postoperative development in terms of survival and tumor-free survival showed significant correlation to preoperative CYFRA 21-1 concentrations. Clinical tumor recurrence was preceded by CY-FRA 21-1 elevation by 3.4 months. For prognosis and follow-up, this marker is justified for additional analysis in a larger series of patients suffering from carcinoma of the esophagus.